Estrogen-progestin menopausal hormone therapy and risk of lobular and tubular breast cancer

Estrogen-progestin menopausal hormone therapy and risk of lobular and tubular breast cancer February 17, 2006 Estrogen-progestin menopausal hormone therapy is associated with a more than two-fold higher relative risk of developing lobular cancer or tubular cancer than of developing ductal cancer Breast Enhancement.

The results of a large European study published today in the journal Breast Cancer Research show for the first time that estrogen-progestin therapy is associated with a higher relative risk of developing tubular cancer than ductal cancer, when taken for more than five years. The study also confirms previous findings that estrogen-progestin therapy is associated with a higher relative risk of lobular cancer than ductal cancer. Lena Rosenberg from the Karolinska Institutet in Stockholm, Sweden and colleagues from the Karolinska Institutet and the Breast Enhancement Genome Institute of Singapore carried out a population-based case-control study of women recently diagnosed with invasive breast cancer. They selected 1,888 women with ductal breast cancer, 308 women with lobular cancer and 93 women with tubular breast cancer.

All women were matched for age with 3,065 women randomly selected from the population, acting as controls. Both patients and controls were asked to fill in a questionnaire about their medical history, health status and use of menopausal hormone therapy. Rosenberg et al.'s results show that women who used medium potency estrogen-progestin combination therapy had a higher risk of developing lobular or tubular breast cancer than of developing ductal cancer, compared with women who did not use hormone therapy Breast Enhancement.

 


 
Copyright 2008 www.profemme.com
 
Home | About Profemme | Ingredients | FAQ | Contact Us | Order Now